Physician profile
Dara U Otu
NPI 1396031688
$3,874.39
in general payments reported to CMS, 2019-2025
28 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $440 · 2021: $16.00 · 2022: $462 · 2023: $624 · 2024: $606 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $763.05 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $602.98 | 2019-2024 | Breztri, Airsupra, Symbicort |
| Philips North America LLC | $326.19 | 2019-2024 | (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.36 | 2019-2025 | Ofev, Stiolto Respimat |
| Mylan Specialty L.P. | $267.52 | 2019-2024 | Yupelri |
| Baxter Healthcare | $171.28 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $167.97 | 2024-2025 | |
| Ceribell, INC. | $163.45 | 2023 | Ceribell Rapid Response Eeg |
| Merck Sharp & Dohme LLC | $115.54 | 2019-2023 | |
| Abbvie INC. | $112.19 | 2020 | |
| Grifols USA, LLC | $106.47 | 2019-2025 | Prolastin-C Liquid |
| Tactile Systems Technology INC | $99.46 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Advanced Respiratory, INC | $93.89 | 2019 | |
| Insmed, INC. | $85.04 | 2019-2023 | Arikayce |
| Electromed, INC. | $84.56 | 2019-2025 | Smartvest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $55.56 | 2024 | Dupixent |
| Sunovion Pharmaceuticals INC. | $48.45 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $42.17 | 2019 | |
| Abiomed | $40.23 | 2024 | Impella |
| Amgen INC. | $32.56 | 2022-2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $31.72 | 2020 | |
| Verona Pharma, INC. | $26.04 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $21.85 | 2020 | |
| Genentech USA, INC. | $21.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.01 | 2020 | |
| Inogen, INC. | $18.90 | 2022 | |
| Mallinckrodt Enterprises LLC | $17.83 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.60 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Otu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.